Data Insights

Spesolimab by Boehringer Ingelheim International for Pyoderma Gangrenosum: Likelihood of Approval

Spesolimab is under clinical development by Boehringer Ingelheim International and currently in Phase II for Pyoderma Gangrenosum. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Spesolimab in Pyoderma Gangrenosum

Data Insights

BI-765845 by Boehringer Ingelheim International for Myocardial Infarction: Likelihood of Approval

BI-765845 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Myocardial Infarction. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BI-765845 in Myocardial Infarction

Data Insights

BI-1569912 by Boehringer Ingelheim International for Major Depressive Disorder: Likelihood of Approval

BI-1569912 is under clinical development by Boehringer Ingelheim International and currently in Phase II for Major Depressive Disorder. According to...

Likelihood of Approval and Phase Transition Success Rate Model - BI-1569912 in Major Depressive Disorder

Data Insights

Ezabenlimab by Boehringer Ingelheim International for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Ezabenlimab in Triple-Negative Breast Cancer (TNBC)

Data Insights

Brigimadlin by Boehringer Ingelheim International for Metastatic Biliary Tract Cancer: Likelihood of Approval

Brigimadlin is under clinical development by Boehringer Ingelheim International and currently in Phase II for Metastatic Biliary Tract Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Brigimadlin in Metastatic Biliary Tract Cancer

Data Insights

Brigimadlin by Boehringer Ingelheim International for Soft Tissue Sarcoma: Likelihood of Approval

Brigimadlin is under clinical development by Boehringer Ingelheim International and currently in Phase I for Soft Tissue Sarcoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Brigimadlin in Soft Tissue Sarcoma

Data Insights

Ezabenlimab by Boehringer Ingelheim International for Colorectal Cancer: Likelihood of Approval

Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase II for Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ezabenlimab in Colorectal Cancer

Data Insights

YH-25724 by Boehringer Ingelheim International for Obesity: Likelihood of Approval

YH-25724 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Obesity. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - YH-25724 in Obesity

Data Insights

Ezabenlimab by Boehringer Ingelheim International for Gastric Cancer: Likelihood of Approval

Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ezabenlimab in Gastric Cancer

Data Insights

BI-1823911 by Boehringer Ingelheim International for Metastatic Colorectal Cancer: Likelihood of Approval

BI-1823911 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Metastatic Colorectal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - BI-1823911 in Metastatic Colorectal Cancer

Data Insights

Spesolimab by Boehringer Ingelheim International for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair): Likelihood of Approval

Spesolimab is under clinical development by Boehringer Ingelheim International and currently in Phase III for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo...

Likelihood of Approval and Phase Transition Success Rate Model - Spesolimab in Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair)

Data Insights

Survodutide by Boehringer Ingelheim International for Obesity: Likelihood of Approval

Survodutide is under clinical development by Boehringer Ingelheim International and currently in Phase III for Obesity. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Survodutide in Obesity

Data Insights

YH-25724 by Boehringer Ingelheim International for Obesity: Likelihood of Approval

YH-25724 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Obesity. According to GlobalData, Phase...

Data Insights

Ezabenlimab by Boehringer Ingelheim International for Gastric Cancer: Likelihood of Approval

Ezabenlimab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Gastric Cancer. According to GlobalData,...

Data Insights

Spesolimab by Boehringer Ingelheim International for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair): Likelihood of Approval

Spesolimab is under clinical development by Boehringer Ingelheim International and currently in Phase III for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo...

Data Insights

Survodutide by Boehringer Ingelheim International for Obesity: Likelihood of Approval

Survodutide is under clinical development by Boehringer Ingelheim International and currently in Phase III for Obesity. According to GlobalData, Phase...

Data Insights

BI-765423 by Boehringer Ingelheim International for Pulmonary Fibrosis: Likelihood of Approval

BI-765423 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Pulmonary Fibrosis. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BI-765423 in Pulmonary Fibrosis

Data Insights

BI-771716 by Boehringer Ingelheim International for Geographic Atrophy: Likelihood of Approval

BI-771716 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Geographic Atrophy. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BI-771716 in Geographic Atrophy

Data Insights

BI-905711 by Boehringer Ingelheim International for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval

BI-905711 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas....

Likelihood of Approval and Phase Transition Success Rate Model - BI-905711 in Metastatic Adenocarcinoma of The Pancreas

Data Insights

Brigimadlin by Boehringer Ingelheim International for Non-Small Cell Lung Cancer: Likelihood of Approval

Brigimadlin is under clinical development by Boehringer Ingelheim International and currently in Phase I for Non-Small Cell Lung Cancer. According...